Mn Services Vermogensbeheer B.V. Buys 5,200 Shares of Eli Lilly and Company $LLY

Key Points

• Mn Services Vermogensbeheer B.V. increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% during the 2nd quarter, now owning 301,388 shares valued at approximately $234.9 million.
• Eli Lilly's recent earnings report showed EPS of $6.31, surpassing analysts' estimates and reflecting a 37.6% increase in quarterly revenue year-over-year.
• The company announced a quarterly dividend of $1.50 per share, resulting in an annualized yield of 0.8%, with a payout ratio of 39.22%.

Mn Services Vermogensbeheer B.V. boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 301,388 shares of the company's stock after purchasing an additional 5,200 shares during the period. Eli Lilly and Company makes up about 1.6% of Mn Services Vermogensbeheer B.V.'s portfolio, making the stock its 9th largest holding. Mn Services Vermogensbeheer B.V.'s holdings in Eli Lilly and Company were worth $234,941,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG increased its stake in Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after buying an additional 2,568 shares during the last quarter. Breed s Hill Capital LLC raised its holdings in shares of Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock valued at $1,101,000 after purchasing an additional 969 shares during the period. Finally, Continuum Advisory LLC boosted its holdings in shares of Eli Lilly and Company by 6.2% during the fourth quarter. Continuum Advisory LLC now owns 1,594 shares of the company's stock worth $1,230,000 after acquiring an additional 93 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $9.41 during trading on Friday, reaching $753.52. 7,319,147 shares of the company traded hands, compared to its average volume of 3,181,974. The firm has a 50 day simple moving average of $738.37 and a 200-day simple moving average of $771.89. The stock has a market capitalization of $713.18 billion, a PE ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.86. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Company insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. JPMorgan Chase & Co. lowered their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Berenberg Bank reiterated a "hold" rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.